Keefe, Bruyette & Woods upgrades CME Group to Outperform, citing undervaluation despite ongoing litigation over perpetual futures contracts. The firm maintains its $305 price target, suggesting 21% upside from current levels. Analyst Chris Allen notes the recent price drop stems from overstated fears about perpetual futures, which he argues pose minimal risk to CME’s core business.
CME Group’s stock has declined 8% year-to-date and 17% monthly, driven by regulatory scrutiny around its perpetual futures offerings. CEO Terry Duffy confirmed plans to sue the Commodity Futures Trading Commission (CFTC) over the approval of these contracts, emphasizing the firm’s commitment to legal compliance.
Despite the volatility, consensus among Wall Street analysts remains bullish. Of 17 analysts covering CME Group, eight recommend buying or strongly buying the stock. Analysts highlight CME’s low retail exposure in perpetual futures and its strong position in equities index licensing as key differentiators that mitigate systemic risks.
Also Read
- Ukrainian Drone Strike Launches Major Assault on Moscow
- Pakistan PM Orders Immediate Fuel Price Cuts Amid Falling Global Oil Prices, New Transparency Measures
- Fed’s Rate Hike Signals Hit Gold and Silver Prices Amid Peace Agreement Uncertainty
- Defense Secretary Pete Hegseth Launches Six‑Month Assessment of U.S. Force Deployment in Europe
